We deliver next-generation biological solutions that transform regional tissue healing standards. By deploying advanced autologous technologies like ActiGraft+, we harness the patient’s own whole peripheral blood to create a living, active biological scaffold right at the bedside. This innovative point-of-care approach replaces dysfunctional cell matrices, targets complex chronic ulcers, and accelerates natural dermal recovery. Our purpose-driven wound care protocols eliminate complex capital equipment dependencies, allowing local medical facilities to provide superior cellular therapies that optimize healing timelines.

Our primary clinical initiative centers on protecting patient mobility and stopping the progression of severe, non-healing wounds. Stalled diabetic foot ulcers and deep venous injuries frequently lead to severe bone infections and preventable lower-limb loss. By introducing restorative blood clot systems like Actigraft+ we are able to help clinicians successfully close complex non-healing wounds before critical complications take root. This multi-layered intervention preserves limbs, protects physical independence, and lowers the long-term surgical risks for vulnerable populations that help patients heal.

Resolving chronic, non-healing wounds is a critical factor in extending long-term patient survival rates. Medical data consistently demonstrates that chronic tissue ulcers and subsequent lower-extremity amputations significantly elevate systemic strain and mortality risks. By equipping regional healthcare networks with advanced microbicidal shields and immediate cellular matrices, we actively mitigate dangerous systemic infection risks and reduce antibiotic dependency. Our dedication to definitive, rapid wound closure restores systemic health, improves quality of life metrics, and grants patients a healthier, longer lifespan. See Study.